[ad_1]
The “Next-Generation Antibody Market Forecast to 2028 – COVID-19 Impact and Global Analysis By Therapeutic Area and Technology” report has been added to ResearchAndMarkets.com’s offering.
The global next-generation antibody market is expected to reach US$ 12,050.13 million by 2028 from US$ 5,428.41 million in 2021; it is estimated to grow at a CAGR of 11.9% from 2021 to 2028.
Factors such as the increasing prevalence of cancer and growing demand for next-generation antibody therapeutics are boosting the market growth. However, complications associated with the manufacturing and approvals hamper the growth of the next-generation antibody market.
Next-generation antibodies are designed to be more specific and often more potent than traditional monoclonal antibodies. Next-generation antibody strategies are required to engineer a useful therapeutic combining antibody, payload, linker, and conjugation method while ensuring stability, targeted delivery, and limited off-target effects.
The next-generation antibody market is segmented on the basis of therapeutic area, technology, and geography. Based on therapeutic area, the market is bifurcated into oncology and autoimmune or inflammatory. The oncology segment held a larger share of the market in 2021. Moreover , the same segment is expected to register a higher CAGR during the forecast period. Based …
Full story available on Benzinga.com
[ad_2]
Source link
